IDiyas

For the Inventor, By the Inventor

Madison, CT, United States of America

Yong-Jin Wu

USPTO Granted Patents = 45 

 

Average Co-Inventor Count = 2.4

ph-index = 7

Forward Citations = 222(Granted Patents)


Location History:

  • East Lyme, CT (US) (2000 - 2002)
  • Princeton, NJ (US) (2019 - 2020)
  • Madison, CT (US) (2001 - 2023)

Company Filing History:

goldMedal28 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal14 out of 4,455 
 
Pfizer Corporation
 patents
bronzeMedal2 out of 1,153 
 
Vanderbilt University
 patents
4. 1 out of 41 
 
Bristol Meyers Squibb Company
 patents

Years Active: 2000-2024

Loading Chart...
Loading Chart...
45 patents (USPTO):
1. 12110290 - Triazolopyridinyl compounds as kinase inhibitors (2024-10-08),
2. 11767322 - Triazolopyridinyl compounds as kinase inhibitors (2023-09-26),
3. 11618753 - Aminopyrrolotriazines as kinase inhibitors (2023-04-04),
4. 10836758 - Acyl sulfonamide NaV1.7 inhibitors (2020-11-17),
5. 10526323 - Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2020-01-07),
6. 10227343 - Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction (2019-03-12),
7. 9475784 - 4,6-diarylaminothiazines as BACE1 inhibitors and their use for the reduction of beta-amyloid production (2016-10-25),
8. 8710061 - Compounds for the reduction of β-amyloid production (2014-04-29),
9. 8637525 - Compounds for the reduction of beta-amyloid production (2014-01-28),
10. 8637523 - Compounds for the reduction of beta-amyloid production (2014-01-28),
11. 8604024 - Compounds for the reduction of beta-amyloid production (2013-12-10),
12. 8598161 - Compounds for the reduction of beta-amyloid production (2013-12-03),
13. 8486952 - Compounds for the reduction of β-amyloid production (2013-07-16),
14. 8349880 - Bicyclic compounds for the reduction of beta-amyloid production (2013-01-08),
15. 7772221 - Diaminopropane derived macrocycles as inhibitors of β amyloid production (2010-08-10),

Title: **Yong-Jin Wu: A Pioneer in Kinase Inhibitor Research**

Introduction

Yong-Jin Wu, a prominent inventor based in Madison, CT, has made significant contributions to the field of pharmacology through his innovative work on kinase inhibitors. With an impressive portfolio of 43 patents, Wu's research has played a pivotal role in advancing therapeutic options for various diseases.

Latest Patents

Among his latest inventions are his patents on triazolopyridinyl compounds as kinase inhibitors. These compounds, characterized by the formula (I) along with their enantiomers, diastereomers, stereoisomers, and pharmaceutically acceptable salts, serve as crucial kinase modulators. Notably, these compounds have shown potential in modulating RIPK1, which is important for therapeutic applications.

Career Highlights

Wu's distinguished career includes significant positions at major pharmaceutical companies. He worked at Bristol-Myers Squibb Company, where he contributed to various drug development projects. He also held a position at Pfizer Corporation, further enhancing his expertise in innovative chemical compounds and their applications in drug discovery.

Collaborations

Throughout his career, Yong-Jin Wu has collaborated with notable professionals, including Jason M. Guernon and Huan He. Their teamwork has led to advancements in the research and development of new therapeutic agents, showcasing the importance of collaboration in scientific research.

Conclusion

Yong-Jin Wu stands out as a leading inventor in the field of kinase inhibitors. His extensive patent portfolio reflects his dedication to innovating new treatments that have the potential to improve patient outcomes. With his continued contributions, Wu remains a key figure in the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…